Intellia Therapeutics Files Comprehensive 2025 Annual Report, Details Clinical Progress, Financials, and Liquidity
NTLA has more than doubled off its 52-week low of $5.9.
Summary
Intellia Therapeutics filed its 2025 annual report, revealing a reduced net loss, increased collaboration revenue, and a liquidity runway into the second half of 2027. The report also provided detailed updates on its clinical pipeline, including the partial lifting of a clinical hold for Nex-z and progress towards commercialization for Lonvo-z, alongside ongoing legal challenges.
Key Events · Earnings and Guidance · NTLA
-
Improved Financial Performance
Reported a net loss of $412.7 million for 2025, an improvement from $519.0 million in 2024, with collaboration revenue increasing to $67.7 million.
-
Extended Liquidity Runway
Projects sufficient cash, cash equivalents, and marketable securities of $605.1 million as of December 31, 2025, to fund operations into the second half of 2027.
-
Lonvo-z (HAE) Advances Towards Commercialization
Phase 3 HAELO study enrollment completed, with topline data expected by mid-2026 and a planned U.S. commercial launch in the first half of 2027.
-
Partial Lifting of Nex-z (ATTR) Clinical Hold
The FDA lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial (ATTRv-PN) in January 2026, but the hold remains for the MAGNITUDE Phase 3 trial (ATTR-CM) following a patient death.
Analysis · NTLA · Life Sciences
This 10-K provides a comprehensive overview of Intellia Therapeutics' financial and operational performance for 2025. While the company reported a significant net loss of $412.7 million, this represents an improvement from the prior year's $519.0 million loss, with collaboration revenue increasing to $67.7 million. The company projects a liquidity runway into the second half of 2027, which is crucial for a clinical-stage biotech. Key clinical updates include the completion of enrollment for the Phase 3 HAELO study for Lonvo-z, with topline data expected by mid-2026 and a planned U.S. launch in H1 2027. However, the ongoing clinical hold for the MAGNITUDE Phase 3 trial of Nex-z (ATTR-CM) due to a patient death remains a significant concern, despite the lifting of the hold for the MAGNITUDE-2 trial (ATTRv-PN) in January 2026. The discontinuation of the NTLA-3001 program and multiple pending lawsuits add to the company's risk profile. Investors should monitor the resolution of the Nex-z clinical hold and the upcoming Lonvo-z data.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NTLA was trading at $13.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $5.90 to $28.25. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.